Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line
VP Rebecca Morison said the ankylosing spondylitis indication adds more evidence of Taltz's benefits. She noted Lilly believes there should be fewer steps before AS patients access IL-17 inhibitors.
You may also be interested in...
Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.
Lilly’s newer diabetes drugs are selling well, although Trulicity numbers disappointed analysts, and are among the firm’s growth-drivers. Longtime diabetes head Enrique Conterno will be succeeded by insider Mike Mason.
Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.